Slides
Page 1
1 Novartis Q3 Results | October 27, 2026 Content Company overview Financial review Click below to navigate through the document References Conclusions Appendix Q3 2026 Results Investor presentation October 27, 2026
Page 2
2 Novartis Q3 Results | October 27, 2026 Content Company overview Financial review Click below to navigate through the document References Conclusions Appendix Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potential,” “expected,” “will,” “plan,” “pipeline,” “outlook,” “confident,” or similar expressions, or by express or implied discussions regarding: potential new products, potential new indications for existing products, potential product launches or potential future revenues from any such products; or results of ongoing clinical trials; potential future, pending or announced transactions; potential future sales or earnings; strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; our capital structure. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this presentation will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. Neither can there be any guarantee that the expected benefits or synergies from the transactions described in this presentation will be achieved in the expected timeframe, or at all. In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; the success of key products, commercial priorities and strategy; the research and development of new products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; the development or adoption of new technologies, including artificial intelligence, and new business models; the implementation of our new IT projects and systems; potential significant breaches of information security or disruptions of our information technology systems; actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this presentation; safety, quality, data integrity, or manufacturing issues; our performance on and ability to comply with environmental, social and governance measures and requirements; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; future global exchange rates; future demand for our products; and other risks and factors referred to in Novartis AG’s most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this presentation as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. All trademarks in this presentation are the property of their respective owners. This presentation includes non-IFRS financial measures, including constant currencies (cc), core results and free cash flow. An explanation of non-IFRS measures can be found on page 45 of the Novartis Condensed Interim Financial Report. 2Novartis Q3 Results | October 27, 2026
Page 3
3 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 Vas Narasimhan, M.D. Chief Executive Officer Company overview
Page 4
4 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 Novartis delivered sales growth and core1 margin expansion in Q3, supporting an upgrade to FY 2026 bottom -line guidance Novartis Q3 Results | October 27, 2026 4 1. Constant currencies (cc) and core results are non -IFRS measures. An explanation of non -IFRS measures can be found on page 45 of the Novartis Condensed In terim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. 2. Kisqali, Kesimpta, Scemblix, Pluvicto, Cosentyx, Leqvio, Fabhalta, and Rhapsido. 3. Definition consi stent with the Condensed Interim Financial Report. 4. See detailed guidance assumptions on page 21. Q3 pipeline highlights Remibrutinib positive PhIII REMODEL -1 and -2 results in RMS Rhapsido® FDA approval in most prevalent form of CIndU Pluvicto® FDA and CN approvals in mAPMN/S prostate cancer Pelabresib EU submission completed in MF Del-zota FDA priority review granted for DMD44Core1 OpIncSales 3.4 2.2 4.9 5.0 5.6 7.3 Q3 2025 Q3 2026 13.9 14.5 Growth Drivers2 Base Business Gx3 +29% 5.5 6.0 Q3 2025 Q3 2026 41.6%39.3%Core margin +4% FY 2026 core operating income guidance upgraded to be in line to grow low single -digit4 +10% USD bn, % cc1
Page 5
5 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 Priority brands and launches continued to show strong growth, demonstrating the replacement power of the business 5 1. Constant currencies (cc) is a non-IFRS measure. An explanation of non -IFRS measures can be found on page 45 of the Novartis Condensed Interim Financial R eport. Unless otherwise noted, all growth rates refer to same period in PY. nm = not meaningful. Sales USD million Growth vs. PY USD million Growth vs. PY cc1 1,821 37% 1,484 22% 593 67% 506 63% 1,857 9% 674 20% 101 nm 237 60% 492 262 235 198 159 110 101 88 Strong growth +29% cc1 GROWTH Novartis Q3 Results | October 27, 2026 Q3 Sales
Page 6
6 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 Sales evolution USD m, % cc Kisqali® Q3 sales grew +37% cc, continuing to outperform CDK4/6 market Novartis Q3 Results | October 27, 2026 6 See page 90 for references (footnotes 1 -6). Constant currencies (cc) is a non -IFRS measure. An explanation of non -IFRS measures can be found on page 45 of the Novartis Condensed Interim Financial Report . Unless otherwise noted, all growth rates refer to same period in PY. US: +38% in Q3, USD 3bn+ YTD • eBC market leader: NBRx share +3%pts vs. PQ, 53% of patients from exclusive population • mBC market leader: Growing NBRx share in 1L, now at 55% • Continued to grow prescriber base vs. PY: +12% overall, +44% in eBC3 Ex-US: +35% cc in Q3 • Continued mBC leadership in NBRx (56%) and TRx (47%)4 • Growth accelerating with eBC launches; now approved in 84 countries and reimbursed in 43 • Clear eBC leadership in DE (80%), UK (77%)2, strong share gains in CN (55%)5 US eBC NBRx1 0% 10 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % Se p- 24 Oc t-24 Nov- 24 Dec- 24 Jan -25 Feb -25 Mar-25 Apr-25 Ma y- 25 Jun -25 Jul- 25 Au g- 25 Se p- 25 Oc t-25 Nov- 25 Dec- 25 Jan -26 Feb -26 Mar-26 Apr-26 Ma y- 26 Jun -26 Jul- 26 Au g- 26 NBRx 844 1,168 485 653 Q3 2025 Q3 2026 1,329 +37% US Ex-US GROWTH DE eBC NBRx2 0% 10 % 20 % 30 % 40 % 50 % 60 % 70 % 80 % 90 % 10 0% Kisqali Competitor 1 Competitor 2 Kisqali Competitor 1 Competitor 2 NBRx 1,821 NATALEE 6-year data6, including clinically meaningful OS (HR 0.809; 95% CI: 0.661-0.989), expected to support continued growth
Page 7
7 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 Sales evolution USD m, % cc US Ex-US Kesimpta® Q3 sales grew +22% cc, fueled by continued strong demand US: +21% cc in Q3 • TRx growth1 outpacing the market, +3%pts in MS (~16% share) and +4.5%pts in B-cell class (~27% share) vs. PY • Continuing to be prescribed earlier in therapy, with 77% of NBRx’s 1L or 1st switch Ex-US: +23% cc in Q3 • Strong growth in Europe, treating ~1/6 MS patients2 • ~80% of EU43 patients from 1L or 1st switch Continued evidence generation highlighted at MSToronto • STHENOS (Phase IIIb study) supports 1L initiation of Kesimpta in mildly active patients • ALITHIOS (OLE study) shows sustained high efficacy and a consistent safety and tolerability profile over 8 years • KATHAROS (prospective OL breastfeeding study) supports treatment decisions for women with MS • NEOS (Phase III study) broadens the evidence base in paediatric MS 828 394 478 Q3 2025 1,006 Q3 2026 1,222 1,484 +22% 7 GROWTH Novartis Q3 Results | October 27, 2026 See page 90 for references (footnotes 1 -3). Constant currencies (cc) is a non -IFRS measure. An explanation of non -IFRS measures can be found on page 45 of the Novartis Condensed Interim Financial Report . Unless otherwise noted, all growth rates refer to same period in PY .
Page 8
8 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 Sales evolution USD m, % cc US Ex-US US: +9% in Q3 • Growth driven by pre-taxane setting (70% of business), with use after only 1 ARPI largest contributor • 1L mAPMR (mCRPC) NBRx share of 15%; further share gains vs. ARPIs remains top priority • FDA approval for PSMAddition in August; expect initial uptake in Q4 with acceleration in 2027 Ex-US: +68% cc in Q3 • Accelerating adoption in Europe, Canada and Japan, with continued momentum in China1 • Japan became the fastest market to reach 1,000 patients, supported by ongoing site expansion • China NMPA approval for PSMAddition in August; expect growth acceleration supported by 6x expansion in treatment centers vs. PY Pluvicto® Q3 sales grew +20% cc, driven by strong ex-US momentum and US pre-taxane growth See page 90 for references (footnote 1). Constant currencies (cc) is a non -IFRS measure. An explanation of non -IFRS measures can be found on page 45 of the Novartis Condensed Interim Financial Report . Unless otherwise noted, all growth rates refer to same period in PY. 460 502 104 172 Q3 2025 Q3 2026 564 674 +20% 8 GROWTH Novartis Q3 Results | October 27, 2026
Page 9
9 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 Promising early indicators for PSMAddition launch in US 9Novartis Q3 Results | October 27, 2026 Infusion• Expect 5-10 weeks lead-time for new patients to be treated • Fastest uptake expected in high tumor burden and de novo patient segments where unmet need is highest vs. ADT+ARPI • Continued expansion in community, including urology • Encouraged by early uptake indicators, including new patient orders and highest -ever NBRx in September • >2/3 mAPMN/S (mHSPC) patients managed by HCPs already using Pluvicto or connected to established referral pathways • Broad treatment site access and capacity, with 9/10 patients within 30 miles of site in US • Continued efforts to help address non-clinical aspects, including further shortening time to treatment GROWTH Strong foundation in place Launch dynamics Pre-filled syringe
Page 10
10 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 Sales evolution USD m, % cc US Ex-US Leqvio® grew +63% cc in Q3, reflecting strong demand around the world See page 90 for references (footnotes 1 -4). Constant currencies (cc) is a non -IFRS measure. An explanation of non -IFRS measures can be found on page 45 of the Novartis Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. Novartis obtained global rights to develop, manufacture, and commercialize Leqvi o under license/collaboration agreement with Alnylam Pharmaceuticals. US: +60% in Q3, outgrowing advanced lipid-lowering market1,2,3 • MOTRx growth (+60%) ahead of market (+46%) and main competitor (+46%), reflecting Leqvio’s differentiated persistency • Continued improvement in Medicare NBRx share (+4.9%pts to 22%)4 • Increasing depth in priority health systems (+28% vs. PY), with continued focus on post-event patients and increasing access/acquisition confidence • US label updated with cardiovascular outcomes statement; ORION-4 and V2P readouts anticipated in Q4 and 2027, respectively Ex-US: +65% cc in Q3 • China growth continues post-NRDL as hospital listings expand • Sustained growth in Europe Expanding Leqvio evidence • V-CHALLENGE presented at ESC, showing superior LDL-C lowering vs. bempedoic acid • ORION-4 and V2P design papers published in AHJ 146 234 162 272 Q3 2025 Q3 2026 308 506 +63% 10 GROWTH Novartis Q3 Results | October 27, 2026
Page 11
11 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 Sales evolution USD m, % cc US Ex-US 17% 24% 25% 32% 30% 33% 18 45 50 49 56 27 19 14 15 See page 91 for references (footnotes 1 -5). Constant currencies (cc) is a non -IFRS measure. An explanation of non -IFRS measures can be found on page 45 of the Novartis Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. US: +78% in Q3 • Achieved 1L NBRx leadership with 33% share (+4%pts vs. PQ)1 • Maintained leadership in later lines; expect continued shift in treatment mix from 2L/3L toward 1L3 Ex-US: +46% cc in Q3 • Continued 3L+ NBRx leadership with 77% share across key markets4 • Early-line indication now approved in 69 ex-US countries • JP sustained 1L NBRx leadership, achieving 56% share, DE 1L NBRx share 33%5 JP 1L NBRx Share (Quarterly)2 Q4’2 4 Q1’2 5 Q2’2 5 Q3’2 5 Q4’2 5 Competitor 1 Competitor 3 S cembl ixCompetitor 4Competitor 2 11 GROWTH US 1L NBRx Share (R3M)1 Competitor 1 Competitor 3 S cembl ix Competitor 4Competitor 2 Competitor 5 Q1’2 6 Novartis Q3 Results | October 27, 2026 Q2’26 Scemblix® Q3 sales grew +67% cc, driven by strong US momentum 233 414 125 179 Q3 2025 Q3 2026 358 593 +67%
Page 12
12 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 Sales evolution USD m, % cc US Ex-US Cosentyx® Q3 sales grew +9% cc, with growth in HS and SpA indications Novartis Q3 Results | October 27, 2026 12 See page 91 for references (footnotes 1 -2). Constant currencies (cc) is a non -IFRS measure. An explanation of non -IFRS measures can be found on page 45 of the Novartis Cond ensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. GROWTH US HS Naive NBRx Share (R4W)1 US SpA IV Patient Share2 50% 49% 48% 52% 48% 47% 48% 0% 20% 40% 60% Aug- 25 Oct-25 Dec-2 5 Jan-26 Mar-26 May-26 Jun-26 Aug- 26 14% 33% 49% 4%0% 20% 40% 60% Jul-24 Sep- 24 Nov-2 4 Jan-25 Mar-25 May-25 Jul-25 Sep- 25 Nov-2 5 Jan-26 Mar-26 May-26 Jul-26 Competitor 1 (molecule 1) Cosent yxCompetitor 2 Competitor 1 Competitor 3 Cosent yxCompetitor 2 693 764 Q3 2025 Q3 2026 1,698 1,857 1,005 1,093 +9% US: +9% in Q3 • HS: Market leader with 48% 1L NBRx share1 • SpA: Base business resilient with stable share in a crowded market • Growth benefited from PY RD adjustments Ex-US: +9% cc in Q3 • Continued growth in Europe and most emerging markets Continued indication expansion • PMR: EC approval in October; FDA decision expected Q4 • HS IV: FDA approval in October
Page 13
13 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 Rhapsido® CSU launch momentum continued in Q3; FDA approval in symptomatic dermographism (SD) supports expansion into CIndU Novartis Q3 Results | October 27, 2026 13 See page 91 for references (footnotes 1 -7). GROWTH CSU CIndU Strong launch trajectory in US • >6k prescribers, evenly split allergists/dermatologists1 • >15k patients treated, >70% 1L after AH2 • NBRx share 26%, +3%pts vs. PQ3 • Disciplined contracting, with ~50% access to label; further access expansion anticipated in Q4 and 2027 Building momentum ex-US • Launched in 7 markets; >1k prescribers and >7k patients4 • Strong early uptake in Germany and China FDA approval in SD5 • First and only FDA-approved treatment for SD, most prevalent form of CIndU • ~100k US CIndU patients uncontrolled on AH6; ~2/3 with SD1 • 100% overlap with CSU prescribers, enabling an efficient launch • Global filings across 3 CIndU subtypes7 expected in Q4 2026 Upgraded peak sales guidance for Rhapsido in CSU and CIndU to USD 4bn+
Page 14
14 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 Important readouts for remibrutinib, del -desiran and pelacarsen in Q3 Novartis Q3 Results | October 27, 2026 14 1. Constant currencies (cc) is a non -IFRS measure. An explanation of non -IFRS measures can be found on page 45 of the Novartis C ondensed Interim Financial Report. INNOVATION Phase III HARBOR in DM1 • Primary endpoint of vHOT vs. placebo not met • Evidence of clinical activity in secondary endpoints and exploratory analyses Next steps • Data to be presented at an upcoming medical congress • Full dataset under evaluation ; HA engagement to determine development path • Partial impairment charge of USD 1.9 billion in Q3; carrying amount USD 5.5 billion Phase III HORIZON in CVRR • Primary endpoint of reducing the risk of cardiovascular events vs. placebo not met, despite lower Lp(a) levels achieved Next steps • Data to be presented at AHA Scientific Sessions 2026 in November • Potential future development of DII235 under assessment Phase III REMODEL-1 and -2 in RMS • Primary endpoint met in both trials, significantly reducing ARR vs. teriflunomide • Superiority on all key secondary endpoints • Clinically meaningful delay in disability progression • Robust, favorable safety with no liver safety signal, consistent with approved indications • Data presented at MSToronto2026 in October Next steps • FDA submission expected in Q4 with PRV Remibrutinib Del-desiran Pelacarsen Novartis reaffirmed guidance of 5 -6% cc1 sales CAGR 2025-30 and mid-single-digit cc1 long-term growth outlook
Page 15
15 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 REMODEL: Remibrutinib offers comprehensive disease control and a robust favorable safety profile, without chronic B -cell depletion Novartis Q3 Results | October 27, 2026 15 1. Clinically meaningful delay in disability progression: >92% of patients remained progression -free as assessed by 6mCDP through 24 months, nominal statistical significance. INNOVATION Next steps: Global regulatory filings ongoing; US expected by EOY with priority review voucher Relapses reduced to 1 every ~13 years MRI activity reduced by 65 -70% >92% of patients free from disability progression (6mCDP)1 ~3x more likely to achieve NEDA -3 6-month PIRA reduced by ~30% …with a robust favorable safety profile No liver safety signals No infection imbalances Nearly 50% fewer discontinuations due to AEs Immunomodulation without B -cell depletion Remibrutinib delivered comprehensive disease control…
Page 16
16 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 ~40k ~280k ~60k ~140k ~40k ~85k Total treated nrSPMS1 ~805k Total treated RMS+nrSPMS Total treated RMS ~720k Total Ex-US ~440k Total USOtherAnti-CD20OralNaïve Remibrutinib target population ~30% ~40-100% over time ~45% >38%~100% over time ~85K RMS+nrSPMS patients treated globally 2025 Remibrutinib has the potential to be a USD 4bn+ medicine in RMS, with potential further upside from nrSPMS Novartis Q3 Results | October 27, 2026 16 Treated patients on a DMT. 2025. Source: IQVIA, Spherix Chart Study, Stethos, JMDC, Novartis. Naïve = new patients per year (incidence) that receive a DMT; Oral, CD20 and Other switches = prevalent pat ients on each class (Others = BRACEs and other infusions). Ex -US = Top 7 ex-US markets (EU5, Japan, Canada). 1. nrSPMS is defined by relapse history and includes patients with MRI activity. The ~85k estimate is based on treated non -active SPMS (naSPMS) patients; as nrSPMS is a broader, overlapping population, the estimate may be conservative. INNOVATION
Page 17
17 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 Multiple readouts still expected in 2026, with a strong catalyst path in 2027 Novartis Q3 Results | October 27, 2026 17 INNOVATION Regulatory Studies with announced positive readouts 2026 Cosentyx® PMR approval (US) ianalumab SjD approval (US) Pluvicto mAPMN/S approval (JP) Rhapsido® CIndU submissions (US, EU, JP , CN) remibrutinib RMS submission (US) 2027 del-zota DMD approval (US)2 pelabresib MF approval (EU) remibrutinib RMS approval (US), RMS submissions (EU, JP) Readouts 2026 ianalumab 1L ITP Leqvio® CVRR-LDLC (ORION-4) Rhapsido HS 2027 abelacimab SPAF1 Fabhalta® gMG ianalumab LN, SLE & SSc Kesimpta® MS Q2M dosing Leqvio® CVRR-LDLC (V2P) Zigakibart IgAN 1. Event-driven trial readout. 2. Submitted for accelerated approval. Select assets (expected)Select assets (expected)
Page 18
18 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 Mukul Mehta Chief Financial Officer Financial review and 2026 guidance
Page 19
19 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 Q3 performance with net sales growth at +4% cc 1 and strong core1 margin expansion 19 1. Constant currencies (cc), core results and free cash flow are non -IFRS measures. An explanation of non -IFRS measures can be f ound on page 45 of the Novartis Condensed Interim Financial Report . Unless otherwise noted, all growth rates refer to same period in PY. 2. Operating income, net income and EPS declined mainly due to the USD 1.9 billion partial impairment charge of the del -desiran IPR&D asset. Key figures1 USD million, unless indicated otherwise Q3 2025 Q3 2026 Change vs. PY 9M 2025 9M 2026 Change vs. PY % USD % cc % USD % cc Net sales 13,909 14,522 4 4 41,196 42,043 2 0 Core operating income 5,460 6,036 11 10 16,960 16,873 -1 -2 Core margin 39.3% 41.6% +2.3%pts +2.0%pts 41.2% 40.1% -1.1%pts -0.8%pts Operating income2 4,501 1,843 -59 -61 14,028 10,828 -23 -24 Net income2 3,930 1,196 -70 -71 11,563 7,609 -34 -35 Core EPS (USD) 2.25 2.46 9 8 6.94 6.85 -1 -3 EPS (USD)2 2.04 0.63 -69 -70 5.94 4.01 -32 -33 Free cash flow 6,217 5,111 -18 15,941 14,002 -12 FINANCIAL PROFILE Novartis Q3 Results | October 27, 2026
Page 20
20 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 Continuing our shareholder-friendly capital allocation strategy 1. In CHF. 2. As of September 30, 2026. 20 FINANCIAL PROFILE Novartis Q3 Results | October 27, 2026 Investing in the business Returning capital to shareholders Investments in organic business Ongoing investment in R&D and CapEx Value-creating bolt-ons in Q3 Acquisition of Myricx (closed in Q3) Exercised option for asset acquisition from Sironax Consistently growing annual dividend 1 USD 9.1bn dividend paid in H1 2026 Share buybacks Up to USD 10bn buyback continuing , with up to USD 4.9bn still to be executed 2 Substantial cash generation
Page 21
21 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 Raising Novartis 2026 full year core 1 operating income guidance 1. Constant currencies (cc) and core results are non -IFRS measures. An explanation of non -IFRS measures can be found on page 45 of the Novartis Condensed Interim Financial Report . Unless otherwise noted, all growth rates refer to same period in PY. 21 Expected, barring unforeseen events; growth vs. PY in cc1 FY guidance on other financial KPIs • Core net financial result: Expenses expected to be around USD 1.7bn • Core tax rate: Expected to be around 16.5% FINANCIAL PROFILE Novartis Q3 Results | October 27, 2026 Core1 operating income expected to be in line to grow low single-digit (from low single-digit decline) Net sales expected to grow low single-digit
Page 22
22 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 H2 with strengthened performance and accelerated quarterly sales growth 1. Constant currencies (cc) and core results are non-IFRS measures. An explanation of non-IFRS measures can be found on page 45 of the Novartis Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. 22 2026 growth vs. PY (cc)1 Illustrative FINANCIAL PROFILE Novartis Q3 Results | October 27, 2026
Page 23
23 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Novartis Q3 Results | October 27, 2026 Currency impact vs. PY %pts, assuming late-October exchange rates prevail in 2026 and 2027 Expected currency impact for full year 2026 and 2027 1. Core results are non-IFRS measures. An explanation of non-IFRS measures can be found on page 45 of the Novartis Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. 23 FINANCIAL PROFILE Novartis Q3 Results | October 27, 2026
Page 24
24 Content Click below to navigate through the document Company overview Financial review References Appendix Conclusions Novartis Q3 Results | October 27, 2026 Vas Narasimhan, M.D. Chief Executive Officer Conclusions
Page 25
25 Content Click below to navigate through the document Company overview Financial review References Appendix Conclusions Novartis Q3 Results | October 27, 2026 25 Advanced the pipeline, with positive remibrutinib results in RMS, Rhapsido and Pluvicto label expansions, and first pelabresib filing Delivered sales growth in Q3 driven by priority brands and launches, demonstrating the replacement power of the business Remain on track to deliver our mid-term guidance of 5-6% sales CAGR 2025-2030 and long-term growth outlook Upgraded full-year guidance for core operating income following strong bottom-line performance Novartis Q3 Results | October 27, 2026
Page 26
26 Content Click below to navigate through the document Company overview Financial review References Appendix Conclusions Novartis Q3 Results | October 27, 2026 Upcoming investor event Novartis Q3 Results | October 27, 2026 26 Meet Novartis Management November 18-19, 2026 London, UK Mid-term guidance 2026 -2031 and long-term outlook Updated peak sales potential for key growth drivers Focus on mid- and late-stage pipeline assets to support growth Breakout sessions by therapeutic area Panel session on AI in R&D
Page 27
27 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Appendix
Page 28
28 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations Appendix Novartis Q3 Results | October 27, 2026 2026 selected key events (expected) H1 2026 H2 2026 Status as of end Q3 Regulatory decisions Rhapsido® CIndU3 US US approval in October Pluvicto® mAPMN/S US, JP, CN US & CN approval in Q3 Rhapsido® CSU EU JP EU & JP approval in Q2 Cosentyx® PMR US EU approval in October OAV101 IT SMA JP EU, CN JP approval in Q1, EU approval in Q2, CN submission withdrawn in Q3 Submissions Cosentyx® PMR US, EU, JP US, EU & JP submissions in Q1 Ianalumab SjD US, EU, CN, JP US, EU, CN & JP submissions in Q1 Pelacarsen CVRR-Lp(a) US Will not be submitted Rhapsido® CIndU3 EU, JP, CN Fabhalta® IgAN JP JP submission in Q1 Pelabresib MF EU EU submission in Q3 Vanrafia® IgAN US1, EU JP, CN1 US & EU submissions in Q2, JP & CN in Q3 Del-zota2 DMD US Submitted to the FDA in Q2 Readouts Rhapsido® CIndU3 PhIII (RemIND) Met primary endpoint in Q1 Pelacarsen CVRR-Lp(a) PhIII (HORIZON)4 Did not meet primary endpoint in Q3 Remibrutinib RMS PhIII (REMODEL-1 & -2) Met primary endpoint in Q3 Rhapsido® HS PhIII (RECHARGE 1 & 2)7 Ianalumab 1L ITP PhIII (VAYHIT-1) Ianalumab wAIHA PhIII (VAYHIA) Did not meet primary endpoint in Q1 QCZ484 HTN5 PhII VHB937 ALS PhII (ASTRALS) Did not meet primary endpoint in Q3 Del-desiran2 DM1 PhIII (HARBOR) Did not meet primary endpoint in Q3 Key study starts NIO752 PSP PhIII FPFV PhIII trial started in Q2 Votoplam8 HD PhIII FPFV PhIII trial started in Q1 Farabursen ADPKD PhIII FPFV Remibrutinib FA PhIII FPFV PhIII trial started in Q3 Pelabresib MF PhIII FPFV6 PhIII trial started in Q2 GIA632 Vitiligo PhII FPFV PhII trial started in Q1 Key innovation milestones in 2026 Novartis Q3 Results | October 27, 2026 28 1. For full approval. 2. On February 27, 2026, Novartis successfully completed the acquisition of Avidity Biosciences, Inc. (“Avidity”). 3. SD cohort readout and US filing in 2025, primary e ndpoint met in Cold and Cholinergic Urticaria in 2026. 4. Event-driven trial. 5. PhIII-enabling interim readout. 6. For US, JP & CN registration. 7. 16wk FIR. Readout accelerated from 2027. 8. Novartis has obtained global rights to develop, manufacture, and commercialize votoplam under a License & Collaboration agreement with PTC Therapeutics. INNOVATION
Page 29
29 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Our pipeline projects at a glance Phase I/II Phase III Registration Total Oncology 19 9 1 29 Solid tumors 17 5 0 23 Hematology 2 4 1 6 Immunology 18 7 1 26 Neuroscience 7 10 1 18 Cardiovascular, Renal and Metabolic 14 8 0 22 Others (thereof IB&GH) 12 (9) 4 (4) 1 (1) 17 70 38 4 112 29 INNOVATION Novartis Q3 Results | October 27, 2026
Page 30
30 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis pipeline in Phase I Oncology Code Name Mechanism Indication(s) Solid tumors AM O959 AM O959 DNA PK inhibitor Prostate cancer DJI136 DJI136 DLL3 CAR-T Small cell lung cancer DZR123 tulmimetostat EZH1, EZH2 inhi bitor Metastati c prostate cancer ECI830 ECI830 CDK2 i nhibitor Breast cancer ESP359 2 25Ac-ETN029 Radioligand therapy target DLL3 Solid tumors FML539 1 77Lu-DWJ155 Radioligand therapy target HER2 Solid tumors FXX489 1 77Lu-NNS309 Radioligand therapy target FAP Solid tumors GCJ9 04 GCJ9 04 - Solid tumors GVV858 GVV858 - Breast cancer and other advanced solid tumors IEV407 IEV407 - Breast cancer INR731 INR731 - Prostate cancer RAE346 RAE346 Pan-mutant-selective PI3Ka inhibi tor Breast cancer Immunology Code Name Mechanism Indication(s) DCY636 DCY636 - Atopic dermatitis PIT565 PIT565 Anti-CD19, Anti-CD3, Anti-CD2 Systemi c lupus erythematosus Rheumatoid arthritis YTB323 rapcabtagene autoleucel CD19 CAR-T Rheumatoid arthritis and severe, refrac tory Sjögren’s diseas e Neuroscience Code Name Mechanism Indication(s) EDK060 EDK060 - Charcot-Marie-Tooth disease DFT383 DFT383 CTNS gene delivery Cystinosis NIO752 NIO752 Tau antisense oligonucleotide Alzheimer’s disease YTB323 rapcabtagene autoleucel CD19 CAR-T Relapsing multiple scl erosi s Primary progressive multiple sclerosis General ized myasthenia gravis Cardiovascular, Renal and Metabolic Code Name Mechanism Indication(s) CYX082 farabursen MIR17 inhibitor Autosomal dominant polycystic kidney disease HJB647 HJB647 - Heart failure Hypertension OJR5 20 OJR5 20 - CKD 17 lead indications Lead indication 30 INNOVATION Novartis Q3 Results | October 27, 2026
Page 31
31 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis pipeline in Phase II Novartis Q3 Results | October 27, 2026 31 1. Phase I / II. Neuroscience Code Name Mechanism Indication(s) GXV813 GXV813 M4 agonist Schizophrenia Others Code Name Mechanism Indication(s) IB&GH EYU688 EYU688 NS4B inhibitor Dengue fever INE963 INE963 Pl asmodium falciparum inhi bitor Malaria ITU512 ITU512 HbF inducing agent Sickle cell disease KAE609 cipargamin PfATP4 inhibitor Malaria, severe Malaria, uncomplicated LXE408 LXE408 Proteas ome inhibitor Visceral leishmaniasis Chagas PKC412 Rydapt® Multi-targeted kinase inhibitor Acute myeloi d leukemia, pediatrics EDI048 EDI048 CpPI(4)K inhibitor Cryptosporidiosis Others FWY003 FWY003 Factor B inhi bitor Geographic atrophy LNP023 Fabhal ta® CFB inhibitor iAMD PAC001 pacibekitug Anti-IL-6 mAb Thyroid eye diseas e (TED) 22 lead indications Lead indication INNOVATION Immunology Code Name Mechanism Indication(s) DDY391 DDY391 VAV1-directed MGD Psoriatic arthritis Sj ögren’s di sease GHZ3 39 GHZ3 39 IL-13, IL18 inhibitor Atopic dermatitis GIA632 GIA632 IL-15 mAb Atopic dermatitis Lichen planus Vitiligo LOU064 Rhapsido® BTK inhibitor Papulopustular rosacea MAS825 arumaki mig IL1B, IL18 inhibitor Still’s disease VAY736 ianalumab BAFF-R inhibitor, ADCC-mediated B-cell depletory Systemic sclerosis YTB323 rapcabtagene autoleucel CD19 CAR-T Active refractory lupus nephritis Active refractory systemic lupus erythematosus Systemi c sclerosis Myositis ANCA associated vasculitis Cardiovascular, Renal and Metabolic Code Name Mechanism Indication(s) DII235 DII235 siRNA targeting Lp(a) mRNA CVRR-Lp(a) HDY015 HDY015 AGT siRNA & PCSK9 siRNA Hyperchol esterolemia and hypertension LNP023 Fabhal ta® CFB inhibitor Lupus nephritis ANCA associated vasculitis LTP001 LTP001 SMURF1 inhibitor Pulmonary arterial hypertension1 Idiopathic pulmonary fibrosis PAC001 pacibekitug Anti-IL-6 mAb ASCVD PKN605 PKN605 HDAC6 Inhibitor Atrial Fibrillation QCZ4 84 QCZ4 84 AGT siRNA Hypertension YM I024 YM I024 NLRP3 inhibitor CVRR Oncology Code Name Mechanism Indication(s) Solid tumors AAA601 Lutathera® Radioligand therapy target SSTR GEPNET, pediatrics AAA614 AAA614 Radioligand therapy target FAP Solid tumors DZR123 tulmimetostat EZH1, EZH2 inhi bitor Solid tumors & lymphomas JSB462 luxdegalutamide Androgen receptor protein degrader Metastatic castration resistant prostate cancer Metastatic hormone sensitive prostate cancer Hematology ABL001 Scemblix® BCR-ABL STAMP inhibitor Chronic myeloid leukemia, pediatrics YTB323 rapcabtagene autoleucel CD19 CAR-T 1L high-risk large B-cell lymphoma
Page 32
32 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis pipeline in Phase III Novartis Q3 Results | October 27, 2026 32 1. SD cohort readout and US filing in Q4 2025, primary endpoint met in Cold and Cholinergic Urticaria cohorts in 2026 . 2. Metastatic androgen pathway modulation -resistant prostate cancer (mAPMR), previously known as metastatic castration resistant prostate cancer (m CRPC). Oncology Code Name Mechanism Indication(s) Solid tumors AAA601 Lutathera® Radioligand therapy target SSTR Gastroenteropancreatic neuroendocrine tumors AAA617 Pluvicto® Radioligand therapy target PSMA Oligometastatic prostate cancer AAA817 2 25Ac-PSMA-617 Radioligand therapy target PSMA post Lu metastatic androgen pathway modulation-resistant (mAPMR) pros tate cancer2 Metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer 1L2 BYL719 Vijoice® PI3K-alpha inhibitor Lymphatic malformations Hematology LNP023 Fabhal ta® CFB inhibitor Atypi cal hemolytic uraemic syndrome PNH, pediatrics VAY736 ianalumab BAFF-R inhibitor, ADCC-mediated B-cell depletor 1L Immune Thrombocytopeni a 2L Immune Thrombocytopeni a Immunology Code Name Mechanism Indication(s) LOU064 Rhapsido® BTK inhibitor Chronic pruri tus of unknown ori gin Chronic spontaneous urticari a, pediatrics Chronic inducible urticaria¹ Food allergy Hidradenitis suppurativa VAY736 ianalumab BAFF-R inhibitor, ADCC-mediated B-cell depletor Lupus nephritis Systemi c lupus erythematosus Cardiovascular, Renal and Metabolic Code Name Mechanism Indication(s) EXV811 atrasentan Endothelin-1 receptor Inhibitor IgA nephropathy, pediatrics FUB523 zigakibart Anti-APRIL IgA nephropathy KJX839 Leqvio® siRNA (regulation of LDL-C) CVRR (secondary prevention) CVRR (primary prev ention) LNP023 Fabhal ta® CFB inhibitor C3 gl omerulopathy, pediatrics IC-MPGN IgAN, pediatrics MAA868 abelaci mab FXI/FXIa inhibi tor Stroke preventi onin atrial fibrillation Neuroscience Code Name Mechanism Indication(s) BAF312 May zent® S1P1,5 receptor modulator Multiple sclerosis, pedi atrics DWH213 del-brax siRNA DUX4 knockdown Facioscapul ohumeral muscular dystrophy EWF980 del-desiran siRNA DMPK knockdown Myotonic dystrophy type 1 LNP023 Fabhal ta® CFB inhibitor General ized myasthenia gravis LOU064 Remi brutinib BTK inhibitor Multiple sclerosis, relapsing remitting Multiple sclerosis, secondary progressive NIO752 NIO752 Tau antisense oligonucleotide Progressive supranuclear palsy OMB157 Kesimpta® CD20 Antagonist Multiple sclerosis, pedi atrics Multiple sclerosis, new dosing regimen HTT227 votoplam Hunti ngtin Modulator Hunti ngton’s disease Others Code Name Mechanism Indication(s) IB&GH AM G334 Ai movig® CGRPR antagonist Migraine, pediatrics QMF149 Atectura® Breezhaler® LABA + ICS Asthma, pediatrics QVM149 Enerzair® Breezhaler® LABA + LAMA + ICS Asthma, pediatrics SEG101 Adakveo® P-selectin inhi bitor Sickle cell disease, pediatrics 8 lead indications Lead indication INNOVATION
Page 33
33 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis pipeline in registration Immunology Code Name Mechanism Indication(s) VAY736 ianalumab BAFF-R inhibitor, ADCC-mediated B-cell depletor Sj ögren’s di sease 4 lead indications 33 INNOVATION Lead indication Novartis Q3 Results | October 27, 2026 Oncology Code Name Mechanism Indication(s) Hematology DAK539 pelabresib1 BET inhibitor Myelofibrosis Others Code Name Mechanism Indication(s) IB&GH KLU156 Ganaplaci de + lumefantrine Non-artemisinin plasmodium falciparum inhibitor Malaria, uncomplicated Neuroscience Code Name Mechanism Indication(s) KPE179 del-zota2 PMO mediated exon 44 skipping Duchenne muscular dystrophy 1. Filed for EU approval, additional PhIII program (MANIFEST-3) remains ongoing. 2. Filed for accelerated approval
Page 34
34 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations Appendix Novartis Q3 Results | October 27, 2026 cipargamin1 KAE609 Malaria u nco mplicated Novartis submission schedule Novartis Q3 Results | October 27, 2026 34 1. Part of triple combination therapy. 2. EU submission. Non-core TA projectNeuroscienceCRM Immunology Oncology ganaplacide + lumefantrine KLU1 56 Malaria u nco mplicated rap cabt ag en e autoleucel YTB323 Myosi tis pelabresib² DAK539 Myelofib rosis ianalumab VAY736 Sjö gren ’s disea se DII235 DII 235 CVR R-Lp(a) PAC001 PAC001 ASCVD LXE408 LXE408 Visceral leishma nia sis rap cabt ag en e autoleucel YTB323 High-risk large B -cell lymp homa rap cabt ag en e autoleucel YTB323 ANCA associa ted vasculit is QCZ4 84 QCZ484 Hypertensio n LTP001 LTP001 Pulmonary a rterial hypertension JSB462 JSB46 2 Prostate cancer rap cabt ag en e autoleucel YTB323 Sy stem ic s cl ero si s cipargamin KAE609 Malaria severe GHZ3 39 GHZ339 Atopic derm atitis 225Ac-PSMA-617 AAA817 mC RPC 1L re mi brutinib LOU06 4 SPMS del-zota KPE179 DM D GIA632 GIA632 Atopic derm atitis ianalumab VAY736 Lupu s n ephritis ianalumab VAY736 SLE ianalumab VAY736 Sy stem ic s cl ero si s rap cabt ag en e autoleucel YTB323 arLN abelacimab MAA868 SPAF 225Ac-PSMA-617 AAA817 post Lu mCRPC del-brax DWH213 F SH D rap cabt ag en e autoleucel YTB323 ar SL E ianalumab VAY736 1L Im mune Thrombocytopenia ianalumab VAY736 2L Im mune Thrombocytopenia re mi brutinib LOU06 4 Re lapsing multiple sclerosis New Molecular Entities: Lead and supplementary indications LeadSupplementary zigakibart FUB523 IgAN del-desiran EWF98 0 DM 1 votoplam HT T2 27 Hu ntin gton’s d isease 2026 ≥202920282027 INNOVATION NIO752 NIO75 2 PSP DDY391 DDY391 SjD EXV811 EXV811 IgAN, ped. YMI024 YMI02 4 CVR R GIA632 GIA632 Vit il igo GIA632 GIA632 Lich en Pla nus DDY391 DDY391 PsA
Page 35
35 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis submission schedule 1. Event-driven trial endpoint. 2. Kesimpta and Mayzent: Pediatric trial in multiple sclerosis run in conjunction (NEOS). 3. Filed in SD cohort in Q4 2025, filing in Cold and Cholinergic Urticaria in 2026. Atectura® indacaterol + mome tasone, QMF149 Asthma, pe dia trics Scemblix® asc iminib CM L, 2L, p ediatrics Adakveo SEG101 Sickle cell disease, pe diat rics Rydapt® midostaurin Acute myeloid leukem ia, p ediatrics Aimovig® Eren umab Pediatric Migraine Rhapsido® LOU06 4 HS Leqvio® 1 K J X8 39 CVRR (seconda ry pre ven tion ) Vijo ice® BYL719 Lympha tic malformations Rhapsido® 3 LOU06 4 CIn dU Cosentyx® Secukinum ab Polymyalgia rhe umatica Fabhalta® LNP0 23 gMG Fabhalta® LNP0 23 IC-MPGN Lutathera® AAA601 GEP-NETs Fabhalta® LNP0 23 aH US Rhapsido® LOU06 4 FA Mayzent® 2 sipo nim od Multiple scle rosis, pe diat rics Kesimpta® 2 Ofatumu mab Multiple scle rosis, pe diat rics Leqvio® 1 K J X8 39 CVRR (primary prevention) Pl uv icto® AAA617 Oligome tast atic PC Kesimpta® Ofatumu mab MS, ne w dosing re gim en Supplementary indications for existing brands 35 2026 ≥202920282027 INNOVATION Non-core TA projectNeuroscienceCRM Immunology Oncology Rhapsido® LOU06 4 CSU, pediatrics Novartis Q3 Results | October 27, 2026 Existing brands Rhapsido® LOU06 4 CPU O Scemblix ABL001 CML 1L+, ped . Enerzair® Breezhaler® QVM149 Asthma, pe d.
Page 36
36 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Net debt1 increased by USD 15.5bn as the FCF was more than offset mainly by M&A and the annual dividend payment 36 1. Net debt is presented as additional information. An explanation of additional information can be found on page 46 of the N ovartis Condensed Interim Financial Report. 2. Free cash flow is a non -IFRS measure. An explanation of non -IFRS measures can be found on page 45 of the Novartis Condensed Interim Financial Report. USDbn Novartis Q3 Results | October 27, 2026 -21.9 -37.4-16.7 -9.1 -4.8 Others Sep 30, 2026 1.1 Free cash flow2 14.0 Treasury share transactions, net Annual dividendM&A / Intangible assets transactions and other acquisitions, net Dec 31, 2025 -15.5
Page 37
37 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 IR Clinical Studies Includes selected ongoing or recently concluded global trials of Novartis development programs/products which are in confirmatory development or marketed (typically Phase 2b or later). For further information on all Novartis clinical trials, please visit: www.novartisclinicaltrials.com Clinical Trials Update
Page 38
38 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Cardiovascular, Renal and Metabolic Cardiovascular, Renal and Metabolic
Page 39
39 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 3 abelacimab – FXI/FXIa inhibitor NCT05712200 LILAC-TIMI 76 (CMAA868A2302) Indication Stroke prevention in atrial fibrillation (SPAF) Phase Phase 3 Patients 2500 Primary Outcome Measures Efficacy: Time to first event of ischemic stroke or systemic embolism (SE) Safety: Time to first occurrence of Bleeding Academic Research Consortium (BARC) type 3c/5 bleeding Arms Intervention Experimental: Abelacimab (MAA868) Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly. Placebo Comparator: Placebo Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly. Target Patients High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral anticoagulation Readout Milestone(s) 2027 Publication TBD
Page 40
40 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 4 atrasentan – ETA receptor antagonist NCT04573478 ALIGN (CHK01-01) Indication IgA nephropathy Phase Phase 3 Patients 404 Primary Outcome Measures 1) Double-blind period: Change in proteinuria: the change in urine protein:creatinine ratio (UPCR) from baseline to Week 36 (non-SGLT2i stratum). Up to Week 36, or about 9 months. Key secondary endpoint (double-blind period): Change in estimated glomerular filtration rate (eGFR) from baseline to Week 136. Arms Intervention Double-blind period (132 weeks, about 2.5 years): Arm 1, experimental: atrasentan 0.75 mg orally once daily for 132 weeks Arm 2, placebo comparator: placebo orally once daily for 132 weeks Target Patients Patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function Readout Milestone(s) 2023 (primary endpoint for US initial submission) 2026 (final analysis for key secondary endpoint, 2.5 years; completion of double-blind period) Publication Interim analysis (primary endpoint): Heerspink HJL et al. N Engl J Med 2025;392(6):544–554 Final analysis (double-blind period): Heerspink HJL et al. Lancet 2026;407(10546):2387–2401
Page 41
41 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 5 DII235 – siRNA targeting Lp(a) mRNA NCT07235046 (CDII235A12201) Indication Risk reduction in cardiovascular disease w elevated Lp(a) Phase Phase 2b Patients 234 Primary Outcome Measures 1) Time averaged percentage change from baseline in Lp(a) measured between Day 60 and Day 180 2) Difference between DII235 dose 2 and placebo in time-averaged percent change from baseline in Lp(a) measured between Day 60 and Day 360 3) Difference between DII235 dose 4 and placebo in time-averaged percent change from baseline in Lp(a) measured between Day 60 and Day 360 Arms Intervention 1) Placebo Comparator: Arm 1 Placebo 2) Experimental: Arm 2 DII235 dose 1 3) Experimental: Arm 3 DII235 dose 2 4) Experimental: Arm 4 DII235 dose 3 5) Experimental: Arm 5 DII235 dose 4 Target Patients Adults With Elevated Lipoprotein(a) Readout Milestone(s) 2027 Publication TBD
Page 42
42 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 6 Fabhalta® – CFB inhibitorFabhalta® – CFB inhibitor NCT04578834 APPLAUSE-IgAN (CLNP023A2301) Indication IgA nephropathy Phase Phase 3 Patients 518 Primary Outcome Measures Ratio to baseline in urine protein to creatinine ratio (sampled from 24h urine collection) at 9 months Annualized total estimated Glomerular Filtration Rate (eGFR) slope estimated over 24 months Arms Intervention Arm 1 - LNP023 200mg BID Arm 2 - Placebo BID Target Patients Primary IgA Nephropathy patients Readout Milestone(s) 2023 (primary endpoint for US initial submission, 9 months UPCR) 2025 (24 months) Publication Barratt J, Eren N, Kashihara N, et al. Iptacopan in IgA nephropathy – final 24- month data. N Engl J Med. 2026. doi:10.1056/NEJMoa2600743. NCT05755386 APPARENT (CLNP023B12302) Indication Immune complex-mediated membranoproliferative glomerulonephritis Phase Phase 3 Patients 106 Primary Outcome Measures Log-transformed ratio to baseline in UPCR at 6 months [Time Frame: 6 months, double-blind] To demonstrate the superiority of iptacopan compared to placebo in reducing proteinuria at 6 months Log-transformed ratio to baseline in UPCR at the 18-month visit (each study treatment arm) [Time Frame: 18 months] To evaluate the effect of iptacopan on proteinuria at 18 months Log-transformed ratio to 12-month visit in UPCR at the 18-month visit in the placebo arm. [ Time Frame: 18 months ] To evaluate the effect of iptacopan on proteinuria at 18 months Arms Intervention Arm 1 experimental: Drug: iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d) Arm 2 placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d) (both on top of SoC) Target Patients Patients (adults and adolescents aged 12-17 years) with idiopathic IC-MPGN Readout Milestone(s) 2028 Publication Vivarelli M, et al., Kidney International Reports (2023), Iptacopan in idiopathic immune complex-mediated membranoproliferative glomerulonephritis: Protocol of the APPARENT multicenter, randomized Phase III study
Page 43
43 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 7 Leqvio® – siRNA (regulation of LDL-C) NCT03705234 ORION-4 (CKJX839B12301) Indication Secondary prevention of cardiovascular events in patients with elevated levels of LDL-C Phase Phase 3 Patients 16124 Primary Outcome Measures A composite of major adverse cardiovascular events, defined as: Coronary heart disease (CHD) death; Myocardial infarction; Fatal or non-fatal ischaemic stroke; or Urgent coronary revascularization procedure Arms Intervention Arm 1: Every 6 months treatment Inclisiran sodium 300mg (given by subcutaneous injection on the day of randomization, at 3 months and then every 6-months) for a planned median duration of about 5 years Arm 2: Matching placebo (given by subcutaneous injection on the day of randomization, at 3 months and then every 6 months) for a planned median duration of about 5 years Target Patients Patient population with mean baseline LDL-C ≥ 100mg/dL Readout Milestone(s) 2026 (event-driven) Publication TBD NCT05030428 VICTORION-2P (CKJX839B12302) Indication Secondary prevention of cardiovascular events in patients with elevated levels of LDL-C Phase Phase 3 Patients 17004 Primary Outcome Measures 1. Time to First Occurrence of 3P-MACE (3-Point Major Adverse Cardiovascular Events) Arms Intervention Arm 1: Experimental Inclisiran sodium, Subcutaneous injection Arm 2: Placebo Comparator, Placebo Subcutaneous injection Target Patients Participants with established cardiovascular disease (CVD) Readout Milestone(s) 2027 (event-driven) Publication TBD
Page 44
44 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 8 Leqvio® – siRNA (regulation of LDL-C) NCT05739383 VICTORION-1P (CKJX839D12302) Indication CVRR (Primary prevention) Phase Phase 3 Patients 14012 Primary Outcome Measures Time to the first occurrence of 4P-MACE 4-Point-Major Adverse Cardiovascular Events (4P-MACE): composite of cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, and urgent coronary revascularization Arms Intervention Arm 1 Experimental: Inclisiran Sodium 300mg, subcutaneous injection in pre-filled syringe Arm 2 Placebo Target Patients High-risk primary prevention patients Readout Milestone(s) 2029 Publication TBD
Page 45
45 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 9 LTP001 – SMURF1 Inhibitor NCT06649110 (CLTP001A12202) Indication Pulmonary arterial hypertension Phase Phase 2 Patients 232 Primary Outcome Measures Part A- Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs), Baseline to Day 35 Part B-Treatment Period 1: Change in pulmonary vascular resistance (PVR), Baseline to week 24 Part B-Treatment Period 2: Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs), From Day 1 until Week 106 Arms Intervention Experimental: LTP001 Dose 1 Experimental: LTP001 Dose 2 Experimental: LTP001 Dose 3 Comparator: Placebo Target Patients Healthy participants (Part A) and in participants with PAH (Part B) Readout Milestone(s) 2028 Publication TBD
Page 46
46 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 10 PAC001 – anti-IL6 mAb NCT06362759 TRANQUILITY (CPAC001A12201) Indication ASCVD Phase Phase 2 Patients 143 Primary Outcome Measures Evaluate the effects of TOUR006 compared with placebo on hs-CRP Arms Intervention Experimental: TOUR006 - 50 MG 50 mg administered subcutaneously at Day 1 and Day 90 (Placebo administered at 30, 60, 120, and 150 Day timepoints) Experimental: TOUR006 - 25 MG 25 mg administered subcutaneously at Day 1 and Day 90 (Placebo administered at 30, 60, 120, and 150 Day timepoints) Experimental: TOUR006 - 15 MG 15 mg administered subcutaneously at Days 1, 30, 60, 90, 120, and 150 Placebo Comparator: Placebo Administered subcutaneously at Days 1, 30, 60, 90, 120, and 150 Target Patients Patients with Chronic Kidney Disease and Elevated hs-CRP Readout Milestone(s) 2025 Publication Pergola PE et al. ESC 2025; abstract 599
Page 47
47 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 11 pelacarsen – Antisense oligonucleotide (ASO) targeting Lp(a) NCT04023552 Lp(a)HORIZON (CTQJ230A12301) Indication Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein(a) Phase Phase 3 Patients 8323 Primary Outcome Measures Time to the first occurrence of MACE (cardiovascular death, non-fatal MI, non-fatal stroke and urgent coronary re-vascularization) Arms Intervention TQJ230 80 mg injected monthly subcutaneously or matched placebo Target Patients Patients with a history of Myocardial infarction or Ischemic Stroke, or a clinically significant symptomatic Peripheral Artery Disease, and Lp(a) ≥ 70 mg/dL Readout Milestone(s) H2 2026 (event-driven) Publication Cho et al. Design and rationale of the Lp(a)HORIZON trial. American Heart Journal. 2025.
Page 48
48 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 12 QCZ484 – AGT siRNA NCT06857955 (CQCZ484A12201) Indication Hypertension Phase Phase 2 Patients 396 Primary Outcome Measures Change from baseline at Month 3 in mean 24hr systolic blood pressure (SBP) by ambulatory blood pressure measurement (ABPM) Arms Intervention Placebo Comparator: Placebo Control Arm 1: QCZ484 Dose 1 solution for injection Arm 2: QCZ484 Dose 2 solution for injection Arm 3: QCZ484 Dose 3 solution for injection Arm 4: QCZ484 Dose 4 solution for injection Arm 5: QCZ484 Dose 5 solution for injection Target Patients Mild to moderate hypertensive patients Readout Milestone(s) 2026 Publication TBD
Page 49
49 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 13 zigakibart – Anti-APRIL NCT05852938 BEYOND (CFUB523A12301) Indication IgA nephropathy Phase Phase 3 Patients 383 Primary Outcome Measures Change from Baseline to week 104 in eGFR Arms Intervention Arm 1 Experimental: BION-1301 (Zigakibart) 600mg subcutaneous administration every 2 weeks for 104 weeks Arm 2 Placebo Comparator: Placebo subcutaneous administration every 2 weeks for 104 weeks Target Patients Adults with IgA Nephropathy Readout Milestone(s) H1 2027 Publication TBD
Page 50
50 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 14 YMI024 – NLRP3 inhibitor NCT07830719 (CYMI024A12202) Indication Risk reduction in cardiovascular disease Phase Phase 2b Patients 180 Primary Outcome Measures Change from baseline in log-transformed IL-6 Arms Intervention 1) YMI024 Dose 1 2) YMI024 Dose 2 3) YMI024 Dose 3 4) YMI024 Dose 4 5) YMI024 Dose 5 6) Placebo Target Patients Adults With Stable Coronary Artery Disease and Elevated hsCRP Readout Milestone(s) 2027 Publication TBD
Page 51
51 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Novartis Q3 Results | October 27, 2026 Immunology Immunology
Page 52
52 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 16 DDY391 – VAV1-directed MGD NCT07801495 (CDDY391A12201) Indication Psoriatic arthritis Phase Phase 2 Patients 220 Primary Outcome Measures 1) Part A: Number of participants achieving American College of Rheumatology 50 (ACR50) response at week 12 2) Part A and B: Number of participants achieving American College of Rheumatology 50 (ACR50) response at week 12 Arms Intervention Part A: 1) Experimental: DDY391-Schedule 1 Dose A 2) Comparator: Schedule 1 – Matching placebo Part B: 3) Experimental: DDY391-Schedule 1 Dose A 4) Experimental: DDY391-Schedule 1 Dose B 5) Experimental: DDY391-Schedule 1 Dose C 6) Comparator: Schedule 1 – Matching placebo 7) Experimental: DDY391-Schedule 2 Dose C 8) Comparator: Schedule 2 – Matching placebo In all arms participants will, based on treatment response either continue receiving DDY391 or switch to local standard of care (SOC). Target Patients Participants With Moderate to Severe Psoriatic Arthritis Readout Milestone(s) 2028 Publication TBD
Page 53
53 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 17 DDY391 – VAV1-directed MGD NCT07737743 (CDDY391B12201) Indication Sjögren's Disease Phase Phase 2 Patients 334 Primary Outcome Measures 1) Part A and B: Change from baseline in ESSDAI score at week 24 2) Part C: Change from baseline in ESSPRI at week 24 Arms Intervention Part A: 1) Experimental: DDY391 dose level 1 2) Comparator: Matching placebo. At the Week 24 visit, all participants will be randomized to DDY391 dose level 1 or dose level 2. Part B: 3) Experimental: DDY391 dose level 1 4) Experimental: DDY391 dose level 2 5) Experimental: DDY391 dose level 3 6) Comparator: Matching placebo. At the Week 24 visit, all participants will be randomized to DDY391 dose level 1 or dose level 2. Part C: 7) Experimental: DDY391 dose level 1 8) Experimental: Matching placebo. At the Week 24 visit, all participants will be randomized to DDY391 dose level 1 or dose level 2. Target Patients Participants With Sjögren's Disease Readout Milestone(s) 2029 Publication TBD
Page 54
54 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 18 GHZ339 – IL-13, IL-18 inhibitor NCT06947993 PLATFORM-AD (CADPT17A12201) Indication Atopic dermatitis Phase Phase 2 Patients 224 Primary Outcome Measures Change from baseline in the Eczema Area and Severity Index (EASI) score at Week 16 EASI will be used to assess the extend and severity of atopic dermatitis on a scale from 0 to 72 where 72 is worst eczema Arms Intervention Experimental: GHZ339 Dose A, Participants who will receive GHZ339 at dose A during Treatment Period 1 will receive GHZ339 at dose A during Treatment Period 2 Experimental: GHZ339 Dose B, Participants who will receive GHZ339 at dose B during Treatment Period 1 will receive GHZ339 at dose B during Treatment Period 2 Experimental: GHZ339 Dose C. Participants who will receive GHZ339 at dose C during Treatment Period 1 will receive GHZ339 at dose C or A during Treatment Period 2 Experimental: GHZ339 Dose D. Participants who will receive GHZ339 at dose D during Treatment Period 1 will receive GHZ339 at dose D or A during Treatment Period 2 Placebo Comparator: Placebo. Participants who will receive placebo during Treatment Period 1 will receive GHZ339 at dose A during Treatment Period 2 Target Patients Patients with moderate to severe Atopic Dermatitis Readout Milestone(s) Primary 2028 Publication TBD
Page 55
55 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 19 GIA632 – IL-15 mAb NCT07431177 (CGIA632B12201) Indication Non-segmental Vitiligo Phase Phase 2 Patients 210 Primary Outcome Measures Percentage change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) score. Arms Intervention Experimental: GIA632 Arm 1 GIA632 will be administered during the 48-week core period. Experimental: GIA632 Arm 2 GIA632 will be administered during the 48-week core period. Experimental: GIA632 Arm 3 GIA632 will be administered during the 48-week core period. Experimental: GIA632 Arm 4 GIA632 will be administered during the 48-week core period. Placebo Comparator: Placebo Placebo will be administered during the 48-week core period. Target Patients Participants with non-segmental vitiligo Readout Milestone(s) 2028 Publication TBD NCT07220577 (CGIA632A12201) Indication Atopic dermatitis Phase Phase 2 Patients 34 Primary Outcome Measures IGA response at Week 16 defined as clear (0) or almost clear (1) score with at least a 2 point-reduction from baseline Arms Intervention Experimental: GIA632 Active treatment arm Placebo Comparator: Placebo Placebo treatment arm Target Patients Adult Participants With Moderate to Severe Atopic Dermatitis Readout Milestone(s) 2027 Publication TBD
Page 56
56 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 20 GIA632 – IL-15 mAb NCT07775924 ELIPSI (CGIA632C12201) Indication Lichen planus Phase Phase 2 Patients 259 Primary Outcome Measures Number of participants achieving an Investigator Global Assessment (IGA) response Arms Intervention 1) Placebo Comparator: Placebo Participants will receive matching placebo according to the treatment regimen assigned at randomization during the study treatment period. 2) Experimental: GIA632 - Treatment regimen 1 Participants will receive GIA632 according to the treatment regimen assigned at randomization during the study treatment period. 3) Experimental: GIA632 - Treatment regimen 2 Participants will receive GIA632 according to the treatment regimen assigned at randomization during the study treatment period. 4) Experimental: GIA632 - Treatment regimen 3 Participants will receive GIA632 according to the treatment regimen assigned at randomization during the study treatment period. 5) Experimental: GIA632 - Treatment regimen 4 Participants will receive GIA632 according to the treatment regimen assigned at randomization during the study treatment period. Target Patients Participants With Moderate to Severe Cutaneous Lichen Planus Readout Milestone(s) 2028 Publication TBD
Page 57
57 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 21 ianalumab – BAFF-R inhibitor, ADCC-mediated B-cell depletor NCT05126277 SIRIUS-LN (CVAY736K12301) Indication Lupus Nephritis Phase Phase 3 Patients 452 Primary Outcome Measures Frequency and percentage of participants achieving complete renal response (CRR) [ Time Frame: week 72 ] Arms Intervention Arm 1: Experimental - ianalumab s.c. q4w in addition to standard of care (SoC) Arm 2: Experimental - ianalumab s.c. q12w in addition to SoC Arm 3: Placebo comparator - Placebo s.c. q4w in addition to SoC Target Patients Patients with active Lupus Nephritis Readout Milestone(s) Primary 2027 Publication TBD
Page 58
58 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 22 ianalumab – BAFF-R inhibitor, ADCC-mediated B-cell depletor ianalumab – BAFF-R inhibitor, ADCC-mediated B-cell depletor NCT05639114 SIRIUS-SLE 1 (CVAY736F12301) Indication Systemic lupus erythematosus Phase Phase 3 Patients 436 Primary Outcome Measures Proportion of participants on monthly ianalumab achieving Systemic Lupus Erythematosus Responder Index -4 (SRI-4) [ Time Frame: Week 60 ] Arms Intervention Experimental: Ianalumab s.c. monthly Experimental: Ianalumab s.c. quarterly Placebo Comparator: Placebo s.c. monthly Target Patients Patients with active systemic lupus erythematosus (SLE) Readout Milestone(s) 2027 Publication TBD NCT05624749 SIRIUS-SLE 2 (CVAY736F12302) Indication Systemic lupus erythematosus Phase Phase 3 Patients 288 Primary Outcome Measures Proportion of participants achieving Systemic Lupus Erythematosus Responder Index -4 (SRI-4) [ Time Frame: Week 60 ] Arms Intervention Experimental: ianalumab s.c. monthly Placebo Comparator: placebo s.c. monthly Target Patients Patients with active systemic lupus erythematosus (SLE) Readout Milestone(s) 2027 Publication TBD
Page 59
59 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 23 ianalumab – BAFF-R inhibitor, ADCC-mediated B-cell depletor NCT06470048 VENUSS (CVAY736S12201) Indication Systemic sclerosis Phase Phase 2 Patients 200 Primary Outcome Measures 3/5 Revised Composite Response Index in Systemic Sclerosis 25 (rCRISS25) response at Week 52 Arms Intervention Arm 1 Experimental VAY736 (Ianalumab) - Treatment Period 1: Ianalumab subcutaneous (s.c.) injection as defined in the protocol - Treatment Period 2: Open-label (OL) Ianalumab subcutaneous (s.c.) injection as defined in the protocol Arm 2 Placebo Comparator: Placebo - Treatment Period 1: Placebo to Ianalumab subcutaneous (s.c.) injection as defined in the protocol - Treatment Period 2: Open-label (OL) Ianalumab subcutaneous (s.c.) injection as defined in the protocol Target Patients Patients with diffuse cutaneous systemic sclerosis Readout Milestone(s) 2027 Publication TBD
Page 60
60 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 24 ianalumab – BAFF-R inhibitor, ADCC-mediated B-cell depletor NCT07621809 THALASSA (CVAY736A22301) Indication Sjögren´s Disease (high symptom burden) Phase Phase 3 Patients 570 Primary Outcome Measures Change in baseline in SSSD oral dryness score Arms Intervention Arm 1 Experimental VAY736 – 300mg VAY736 once monthly solution for injection for subcutaneous use Arm 2 Placebo Comparator: Placebo Placebo once monthly solution for injection for subcutaneous use Target Patients Participants With Sjögren's Disease With High Symptom Burden Readout Milestone(s) 2029 Publication TBD
Page 61
61 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 25 Rhapsido® – BTK inhibitor NCT05976243 RemIND (CLOU064M12301) Indication Chronic inducible urticaria Phase Phase 3 Patients 362 Primary Outcome Measures 1. Proportion of participants with complete response in Total Fric Score; symptomatic dermographism [ Time Frame: Week 12 ] 2. Proportion of participants with complete response in critical temperature threshold; cold urticaria [ Time Frame: Week 12 ] 3. Proportion of participants with itch numerical rating scale =0; cholinergic urticaria [ Time Frame: Week 12 ] Arms Intervention All arms oral, twice daily: Arm 1 Experimental Remibrutinib, symptomatic dermographism group Arm 2 Placebo symptomatic dermographism group Arm 3 Experimental Remibrutinib, cold urticaria group Arm 4 Placebo cold urticaria group Arm 5 Experimental Remibrutinib, cholinergic urticaria group Arm 6 Placebo cholinergic urticaria group Target Patients Adults suffering from CINDU inadequately controlled by H1-antihistamines Readout Milestone(s) H1 2026 Publication TBD
Page 62
62 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 26 Rhapsido® – BTK inhibitor NCT07768371 (CLOU064I12301) Indication Food allergy Phase Phase 3 Patients 576 Primary Outcome Measures Sub-study 1: Number of participants achieving response status (tolerated at least 600 mg of peanut protein) Sub-study 2: Number of participants achieving response status (tolerated at least 1000 mg of milk protein) Sub-study 3: Number of participants achieving response status (tolerated at least 1000 mg of egg protein) Arms Intervention 1) Experimental: Sub-study 1- LOU064: Participants with peanut allergy will receive remibrutinib during the double-blind treatment period (up to Week 24), 2) Placebo Comparator: Sub-study 1- Placebo: Participants with peanut allergy will receive matching placebo during the double-blind treatment period (up to Week 24) 3) Experimental: Sub-study 2- LOU064: Participants with cow's milk allergy will receive remibrutinib during the double-blind treatment period (up to Week 24) 4) Placebo Comparator: Sub-study 2- Placebo: Participants with cow's milk allergy will receive matching placebo during the double-blind treatment period (up to Week 24) 5) Experimental: Sub-study 3- LOU064: Participants with hen's egg allergy will receive remibrutinib during the double-blind treatment period (up to Week 24) 6) Placebo Comparator: Sub-study 3- Placebo: Participants with hen's egg allergy will receive matching placebo during the double-blind treatment period (up to Week 24) 7) Experimental: Sub-study 4- LOU064: Participants with peanut, cow's milk, and hen's egg allergy will receive remibrutinib during the double-blind treatment period (up to Week 4) 8) Placebo Comparator: Sub-study 4- Placebo: Participants with peanut, cow's milk, and hen's egg allergy will receive matching placebo during the double- blind treatment period (up to Week 4) All arms are followed by open-label remibrutinib treatment through Week 52. Target Patients Adolescent and adult participants with peanut, milk, or egg IgE-mediated allergy. Readout Milestone(s) 2029 Publication TBD
Page 63
63 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 27 Rhapsido® – BTK inhibitor NCT06840392 RECHARGE2 (CLOU064J12302) Indication Hidradenitis suppurativa Phase Phase 3 Patients 565 Primary Outcome Measures Proportion of participants with Hidradenitis Suppurativa clinical response 50 (HiSCR50) at Week 16 Arms Intervention Arm 1: Experimental Participants randomized to receive remibrutinib Dose A during Treatment Period 1 and 2 Arm 2: Experimental Participants randomized to receive remibrutinib Dose B during Treatment Period 1 and 2 Arm 3: Participants randomized to receive placebo during Treatment Period 1 followed by remibrutinib dose B during Treatment Period 2 Target Patients Adult and adolescent patients with moderate to severe Hidradenitis Suppurativa Readout Milestone(s) H2 2026 Publication TBD NCT06799000 RECHARGE1 (CLOU064J12301) Indication Hidradenitis suppurativa Phase Phase 3 Patients 588 Primary Outcome Measures Proportion of participants with Hidradenitis Suppurativa clinical response 50 (HiSCR50) at Week 16 Arms Intervention Arm 1: Experimental Participants randomized to receive remibrutinib Dose A during Treatment Period 1 and 2 Arm 2: Experimental Participants randomized to receive remibrutinib Dose B during Treatment Period 1 and 2 Arm 3: Placebo comparator Participants randomized to receive placebo during Treatment Period 1 followed by remibrutinib dose B during Treatment Period 2 Target Patients Adult and adolescent patients with moderate to severe Hidradenitis Suppurativa Readout Milestone(s) H2 2026 Publication TBD
Page 64
64 Content Click below to navigate through the document Company overview Financial review References Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 28 Rhapsido® – BTK inhibitor NCT07811869 (CLOU064R12302) Indication Chronic pruritus of unknown origin (CPUO) Phase Phase 3 Patients 180 Primary Outcome Measures Proportion of participants achieving ≥4 point reduction from baseline in Worst itch Numerical Rating Scale (WI NRS) Arms Intervention 1) Experimental: Remibrutinib: Remibrutinib film coated tablets 2) Experimental: Placebo followed by remibrutinib: Matching placebo. At the Week 24 visit, all participants will receive active treatment (remibrutinib). Target Patients Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO) Readout Milestone(s) 2029 Publication TBD NCT07700056 (CLOU064R12301) Indication Chronic pruritus of unknown origin (CPUO) Phase Phase 3 Patients 180 Primary Outcome Measures Proportion of participants achieving ≥4 point reduction from baseline in Worst itch Numerical Rating Scale (WI NRS) Arms Intervention 1) Experimental: Remibrutinib: Remibrutinib film coated tablets 2) Experimental: Placebo followed by remibrutinib: Matching placebo. At the Week 24 visit, all participants will receive active treatment (remibrutinib). Target Patients Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO) Readout Milestone(s) 2029 Publication TBD
Page 65
65 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Neuroscience Neuroscience
Page 66
66 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 30 Del-desiran – siRNA DMPK knockdown NCT06411288 HARBOR (CEWF980A12301) Indication Myotonic Dystrophy Type 1 (DM1) Phase Phase 3 Patients 159 Primary Outcome Measures Hand function – video Hand Opening Time (vHOT) Arms Intervention 1) Experimental: Del-desiran Del-desiran (AOC 1001) will be administered seven times 2) Placebo Comparator: Placebo Saline will be administered seven times Target Patients People With DM1 Readout Milestone(s) H2 2026 Publication TBD
Page 67
67 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 31 Del-brax – siRNA DUX4 knockdown NCT07038200 FORTITUDE-3 (CDWH213A12301) Indication Facioscapulohumeral Muscular Dystrophy (FSHD) Phase Phase 3 Patients 200 Primary Outcome Measures Quantitative Muscle Testing (QMT) composite score Arms Intervention 1) Experimental: del-brax Del-brax (AOC 1020) will be administered 13 times 2) Placebo Comparator: placebo Saline will be administered 13 times Target Patients Participants with FSHD Readout Milestone(s) 2028 Publication TBD
Page 68
68 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 32 Del-zota – PMO mediated exon 44 skipping NCT06244082 EXPLORE44OLE (CKPE179A12201) Indication Duchenne Muscular Dystrophy (DMD) Phase Phase 2 Patients 39 Primary Outcome Measures Incidence of Treatment Emergent Adverse Events (TEAEs) Arms Intervention Experimental: AOC 1044 Multiple Dose Levels AOC 1044 will be IV infused every 6 weeks for approximately 2 years. Target Patients Participants with Mutations Amenable to Exon 44 Skipping Readout Milestone(s) 2027 Publication TBD NCT07587242 SAFARI44 (CKPE179A12301) Indication Duchenne Muscular Dystrophy (DMD) Phase Phase 3 Patients 70 Primary Outcome Measures Change from Baseline in Time to Rise (TTR) Velocity at Week 54 Arms Intervention Experimental: AOC 1044 Participants will receive AOC 1044 intravenously (IV) every 6 weeks (Q6W) during the 54-week double-blind treatment period, followed by a 54-week open-label treatment period in which the same participants will continue to receive AOC 1044 IV Q6W Placebo Comparator: Placebo Participants will receive placebo (saline) IV Q6W during the 54-week double-blind treatment period, followed by a 54-week open-label treatment period in which all participants will then receive AOC 1044 IV Q6W Target Patients Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping Readout Milestone(s) 2029 Publication TBD
Page 69
69 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 33 Fabhalta® – CFB inhibitor NCT06517758 APPRAISE (CLNP023Q12301) Indication Generalized Myasthenia Gravis (gMG) Phase Phase 3 Patients 146 Primary Outcome Measures Change from baseline to Month 6 in Myasthenia Gravis Activity of Daily Living (MG-ADL) total score Arms Intervention Participants who meet the eligibility criteria will be randomized in a ratio of 1:1, to receive either iptacopan at a dose of 200 mg orally b.i.d or matching placebo Target Patients Patients with generalized MG who are anti-AchR-positive and are on stable standard of care Readout Milestone(s) 2027 Publication TBD
Page 70
70 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 34 Kesimpta® – anti-CD20 NCT06869785 FILIOS (COMB157Q12301) Indication Multiple Sclerosis new dosing regimen Phase Phase 3 Patients 196 Primary Outcome Measures Ofatumumab plasma pharmacokinetics - area under the curve, up to 12 weeks Arms Intervention Arm 1: Active Comparator Ofatumumab dose 1, Approved dosage Arm 2: Experimental Ofatumumab dose 2, New dosage Target Patients Patients with relapsing multiple sclerosis Readout Milestone(s) 2027 Publication TBD
Page 71
71 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 35 Mayzent® – S1P1,5 receptor modulator / Kesimpta – CD20 antagonist NCT04926818 NEOS (CBAF312D2301) Indication Multiple Sclerosis, pediatrics Phase Phase 3 Patients 129 Primary Outcome Measures Annualized relapse rate (ARR) in target pediatric participants Arms Intervention Arm 1: Experimental ofatumumab - 20 mg injection/ placebo Arm 2: Experimental siponimod - 0.5 mg, 1 mg or 2 mg/ placebo Arm 3: Active Comparator fingolimod - 0.5 mg or 0.25 mg/ placebo Target Patients Children/adolescent patients aged 10-17 years old with Multiple Sclerosis (MS). The targeted enrollment is 120 participants with multiple sclerosis which will include at least 5 participants with body weight (BW) ≤40 kg and at least 10 participants of 10 to 12 years of age overall. There is a minimum 6 month follow up period for all participants (core and extension). Total duration of the study could be up to 7 years. Readout Milestone(s) 2026 Publication TBD
Page 72
72 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 36 NIO752 – Tau antisense oligonucleotide NCT07498426 PRESERVE (CNIO752A12301) Indication Progressive Supranuclear Palsy Phase Phase 3 Patients 300 Primary Outcome Measures Change from baseline in the rPSPRS-10 score Arms Intervention Arm 1: Experimental: NIO752 NIO752 solution Arm 2: Placebo comparator: Placebo Placebo in solution Target Patients Participants with Progressive Supranuclear Palsy Readout Milestone(s) 2029 Publication TBD
Page 73
73 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 37 remibrutinib – BTK inhibitorremibrutinib – BTK inhibitor NCT05147220 REMODEL-1 (CLOU064C12301) Indication Multiple Sclerosis, relapsing Phase Phase 3 Patients 1001 Primary Outcome Measures Annualized relapse rate (ARR) of confirmed relapses [Core Part]. ARR is the average number of confirmed MS relapses in a year Arms Intervention Arm 1: Experimental; Remibrutinib - Core (Remibrutinib tablet and matching placebo of teriflunomide capsule) Arm 2: Active Comparator; Teriflunomide - Core (Teriflunomide capsule and matching placebo remibrutinib tablet) Arm 3: Experimental; Remibrutinib - Extension (Participants on remibrutinib in Core will continue on remibrutinib tablet) Arm 4: Experimental; Remibrutinib - Extension (on teriflunomide in Core) (Participants on teriflunomide in Core will switch to remibrutinib tablet) Target Patients Patients with relapsing Multiple Sclerosis Readout Milestone(s) H2 2026 Publication TBD NCT05156281 REMODEL-2 (CLOU064C12302) Indication Multiple Sclerosis, relapsing Phase Phase 3 Patients 1011 Primary Outcome Measures Annualized relapse rate (ARR) of confirmed relapses Arms Intervention Arm 1: Experimental; Remibrutinib – Core Remibrutinib tablet and matching placebo of teriflunomide capsule Arm 2: Active Comparator; Teriflunomide – Core Teriflunomide capsule and matching placebo remibrutinib tablet Arm 3: Experimental: Remibrutinib – Extension Participants on remibrutinib in Core will continue on remibrutinib tablet Arm 4: Experimental: Remibrutinib - Extension (on teriflunomide in Core) Participants on teriflunomide in Core will switch to remibrutinib tablet Target Patients Patients with relapsing Multiple Sclerosis Readout Milestone(s) H2 2026 Publication TBD
Page 74
74 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 38 remibrutinib – BTK inhibitor NCT07225504 REMASTER (CLOU064P12301) Indication Secondary progressive multiple sclerosis Phase Phase 3 Patients 1275 Primary Outcome Measures Time to 6-month confirmed disability progression (6mCDP) on Expanded Disability Status Scale (EDSS). From baseline up to approximately 5 years. Arms Intervention Arm 1: Experimental: Remibrutinib (LOU064) Core Part: Remibrutinib film-coated tablet taken orally [Extension Part: Open-label remibrutinib film-coated tablet taken orally] Arm 2: Placebo Comparator: Placebo Core Part: Matching placebo film-coated tablet taken orally [Extension Part: Open-label remibrutinib film-coated tablet taken orally] Target Patients Patients with secondary progressive multiple sclerosis (SPMS) Readout Milestone(s) 2030 Publication TBD
Page 75
75 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 39 Votoplam – Huntington modulator NCT07326709 INVEST-HD (CHTT227A12301) Indication Huntington’s Disease (HD) Phase Phase 3 Patients 770 Primary Outcome Measures Change from Baseline in cUHDRS score Arms Intervention Experimental: Votoplam Votoplam (blinded) taken orally, randomized in a 3:2 ratio (Votoplam: Placebo) Placebo Comparator: Placebo Placebo (blinded) taken orally, randomized in a 3:2 ratio (Votoplam: Placebo) Target Patients Participants With Huntington's Disease Readout Milestone(s) 2030 Publication TBD
Page 76
76 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Oncology Oncology
Page 77
77 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 41 225Ac-PSMA-617 – Radioligand therapy target PSMA NCT06855277 AcTFirst (CAAA817B12301) Indication Metastatic castration-resistant prostate cancer Phase Phase 3 Patients 940 Primary Outcome Measures Radiographic Progression Free Survival (rPFS) Arms Intervention Arm 1: Investigational Arm, AAA817+ARPI (enzalutamide or abiraterone) Participants will receive AAA817 infusion directly into a vein with ARPIs. Arm 2: Investigational Arm, AAA817 Participants will receive AAA817 infusion directly into a vein. Arm 3: Control arm, Investigator's choice of SoC (ARPI, taxane-based chemotherapy or [177Lu]Lu-PSMA-617 (AAA617)) Participants will receive standard treatment as decided by the trial doctor either as a chemotherapy infusion directly into a vein, ARPI either as capsules or tablets or [177Lu]Lu-PSMA-617 (AAA617) infusion directly into a vein. Target Patients Adult participants with PSMA-positive metastatic Castration Resistant Prostate Cancer (mCRPC) Readout Milestone(s) 2028 Publication TBD NCT06780670 PSMAcTION (CAAA817A12201) Indication post Lu Metastatic castration-resistant prostate cancer Phase Phase 2/3 Patients 443 Primary Outcome Measures 1) Biochemical response rate (Phase II): Biochemical response rate as defined as the percentage of participants who achieved a ≥ 50% decrease from baseline that is confirmed by a second measurement 2) Adverse Events (AEs) and Serious Adverse Events (SAEs), and deaths - Phase II: Safety defined as the type, incidence and severity of AEs and SAEs, and deaths 3) Tolerability of the proposed dose of AAA817- Phase II: Percentage of participants who experienced Dose interruptions, reductions, discontinuation, dose intensity and duration of exposure 4) Radiographic progression-free survival (rPFS)- Phase III: Percentage of participants who are alive without radiographic progression or who are lost to follow -up at the time of analysis 5) Overall survival (OS)- Phase III: Percentage of participants who are alive or who are lost to follow-up at the time of analysis Arms Intervention Experimental: Phase II: AAA817 Dose A AAA817 Dose A will be given for a number of cycles: a cycle = 8 weeks Experimental: Phase II: AAA817 Dose B AAA817 will be given for a number of cycles; a cycle = 8 weeks Experimental: Phase III: Recommended Phase 3 Dose of AAA817 Rp3D of AAA817 will be given for a number of cycles; a cycle = 8 weeks Active Comparator: Phase III: Investigator's choice of SoC Participants will be given Standard of Care (SOC) treatment per Investigator's choice. Target Patients Adults with PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy Readout Milestone(s) 2028 Publication TBD
Page 78
78 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 42 ianalumab – BAFF-R inhibitor, ADCC-mediated B-cell depletor NCT05653349 VAYHIT1 (CVAY736I12301) Indication 1L Immune Thrombocytopenia Phase Phase 3 Patients 225 Primary Outcome Measures Rate of Stable Response off treatment at 12 months (SROT-12) Arms Intervention Arm 1: Experimental: Ianalumab Lower dose administered intravenously with corticosteroids oral or parentally (if clinically justified) Arm 2: Ianalumab Higher dose administered intravenously with corticosteroids oral or parentally (if clinically justified) Arm 3: Placebo Comparator administered intravenously with corticosteroids oral or parentally (if clinically justified) Target Patients Adult patients with primary ITP Readout Milestone(s) H2 2026 Publication TBD
Page 79
79 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 43 iptacopan – CFB inhibitor NCT05935215 APPRECIATE (CLNP023F12302) Indication Atypical haemolytic uraemic syndrome Phase Phase 3 Patients 50 Primary Outcome Measures Percentage of participants free of TMA manifestation during 12 months after switching from anti-C5 antibodies to iptacopan Arms Intervention Single arm, open-label with adult patients receiving 200mg oral twice daily doses of iptacopan Target Patients Adult patients with aHUS with evidence of response to anti-C5 antibodies Readout Milestone(s) 2028 Publication TBD
Page 80
80 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 44 Lutathera® – Radioligand therapy target SSTR NCT06784752 NETTER-3 (CAAA601A62301) Indication Gastroenteropancreatic neuroendocrine tumors Phase Phase 3 Patients 240 Primary Outcome Measures Progression Free Survival (PFS) centrally assessed by Blinded Independent Review Committee (BIRC) Arms Intervention Arm 1: Experimental: [177Lu]Lu-DOTA-TATE + Octreotide LAR Participants in this arm will receive [177Lu]Lu-DOTA-TATE plus Octreotide long- acting release (LAR). Arm 2: Active Comparator: Octreotide LAR Participants in this arm will receive Octreotide LAR only. Target Patients Patients newly diagnosed with Grade 1 and Grade 2 (Ki-67 <10%) advanced GEP-NET with high disease burden Readout Milestone(s) 2028 Publication TBD
Page 81
81 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 45 Pelabresib – BET Inhibitor NCT04603495 MANIFEST-2 (CDAK539A12301) Indication Myelofibrosis Phase Phase 3 Patients 430 Primary Outcome Measures Number of Participants With Splenic Response by Central Radiology Reads at Week 24 Arms Intervention Experimental: Pelabresib + ruxolitinib Pelabresib monohydrate tablets + ruxolitinib phosphate tablets Active Comparator: Placebo + ruxolitinib Matching placebo tablets + ruxolitinib phosphate tablets Target Patients Myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi) Primary Completion 2023 Publication Raajit K. Rampal et al., "Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial," Nature Medicine, published online March 10, 2025 NCT07357727 MANIFEST-3 (CDAK539A12303) Indication Myelofibrosis Phase Phase 3 Patients 460 Primary Outcome Measures 1) Number of Participants with Splenic Response (SVR35) by Central Radiology Reads at Week 24 in participants with baseline total symptom score (TSS) ≥ 25 2) Absolute change from baseline in total symptom score (TSS) at Week 24 in participants with baseline TSS ≥ 25 3) Number of Participants with Splenic Response (SVR35) by Central Radiology Reads at Week 24 in participants with baseline TSS ≥ 15 4) Absolute change from baseline in total symptom score (TSS) at Week 24 in participants with baseline TSS ≥ 15 Arms Intervention Experimental: Arm 1: Pelabresib + Ruxolitinib Comparator: Arm 2: Placebo + Ruxolitinib Target Patients Patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have not previously received Janus kinase (JAK) inhibitor therapy. Readout Milestone(s) 2028 Publication TBD
Page 82
82 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 46 Pluvicto® – Radioligand therapy target PSMA NCT05939414 PSMA-DC (CAAA617D12302) Indication Oligometastatic prostate cancer Phase Phase 3 Patients 450 Primary Outcome Measures Metastasis Free Survival (MFS) Arms Intervention Arm 1 Experimental: Investigational arm All participants will be treated with Stereotactic Body Radiation Therapy (SBRT) to all metastatic lesions followed by a dose of 7.4 GBq (200 mCi) +/- 10% of AAA617 which will be administered once every 6 weeks (1 cycle) for a planned 4 cycles. Arm 2 No Intervention: Observational arm All participants will be treated with Stereotactic Body Radiation Therapy (SBRT) to all metastatic lesions followed by observation only. Target Patients Participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor Readout Milestone(s) 2028 Publication TBD
Page 83
83 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 47 luxdegalutamide – Androgen receptor protein degrader NCT07047118 LuxAR-02 (CJSB462B12201) Indication Metastatic castration resistant prostate cancer Phase Phase 2 Patients 138 Primary Outcome Measures Efficacy: Prostate Specific Antigen 50 (PSA50) Rate from Baseline at any point, confirmed by a 2nd PSA ≥ 3wks without progression in between Safety: Incidence rate of adverse events (AEs). Tolerability: Number of participants with dose adjustments & Duration of exposure to study treatment Arms Intervention Experimental: Arm 1, JSB462 100 mg QD + AAA617 7.4 GBq Q6W Experimental: Arm 2, JSB462 300 mg QD + AAA617 7.4 GBq Q6W Active Comparator: Arm 3, AAA617 7.4 GBq Q6W Target Patients Adult male patients with PSMA-positive Metastatic Castration Resistant Prostate cancer (mCRPC) Readout Milestone(s) 2027 Publication TBD NCT06991556 LuxAR-03 (CJSB462C12201) Indication Metastatic hormonal sensitive prostate cancer Phase Phase 2 Patients 168 Primary Outcome Measures Efficacy: Prostate Specific Antigen 90 (PSA90) Rate from Baseline at any point, confirmed by a 2nd PSA ≥ 3wks without progression in between Safety: Incidence rate of adverse events (AEs). Tolerability: Number of participants with dose adjustments & Duration of exposure to study treatment Arms Intervention Experimental: Arm 1, JSB462 100 mg QD + abiraterone 1000 mg QD Experimental: Arm 2, JSB462 300 mg QD + abiraterone 1000 mg QD Active Comparator: Arm 3, abiraterone 1000 mg QD or enzalutamide 160 mg QD Target Patients Adult male patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Readout Milestone(s) 2032 Publication TBD
Page 84
84 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 48 Vijoice® – PI3Ki NCT05948943 EPIK-L1 (CBYL719P12201) Indication Lymphatic Malformation Phase Phase 2/3 Patients 232 Primary Outcome Measures Stage 2: Radiological response rate at Week 24 of Stage 2 (adult and pediatric (6 - 17 years of age) participants) Time Frame: Baseline, Week 24 Arms Intervention Arm 1: Experimental. Adult participants, alpelisib dose 1 (Stage 1) Arm 2: Experimental. Adult participants, alpelisib dose 2 (Stage 1) Arm 3: Experimental. Pediatric participants (6-17 years of age), alpelisib dose 2 (Stage 1) Arm 4: Experimental. Pediatric participants (6-17 years of age), alpelisib dose 3 (Stage 1) Arm 5: Experimental. Adult participants, alpelisib (Stage 2) Arm 6: Placebo comparator. Adult participants, placebo (Stage 2) Arm 7: Experimental. Pediatric participants (6-17 years of age), alpelisib (Stage 2) Arm 8: Placebo Comparator. Pediatric participants (6-17 years of age), placebo (Stage 2) Arm 9: Experimental. Pediatric participants (0-5 years of age), alpelisib (Stage 2) Target Patients Pediatric and adult patients with lymphatic malformations associated with a PIK3CA mutation Readout Milestone(s) 2028 Publication TBD
Page 85
85 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 In-market Brands & Global Health In-market Brands & Global Health
Page 86
86 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 50 Ganaplacide+lumefantrine – Non-artemisinin plasmodium falciparum inhibitor NCT05842954 KALUMA (CKLU156A12301) Indication Malaria, uncomplicated Phase Phase 3 Patients 1720 Primary Outcome Measures PCR-corrected adequate clinical and parasitological response (ACPR) at day 29 Arms Intervention Arm 1 experimental: KLU156 oral; 400/480 mg (ganaplacide/ lumefantrine) is the fixed dose combination for patients with a bodyweight ≥ 35kg. Patients < 35kg will take a fraction of the dose according to weight group as defined in the protocol. Arm 2 active comparator: Coartem, oral, dosing will be selected based on patient's body weight as per product's label. Target Patients Adults and children ≥ 10 kg Body Weight with uncomplicated P. Falciparum Malaria including mixed infection Readout Milestone(s) 2025 Publication TBD
Page 87
87 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 51 Rydapt® – Multi-targeted kinase inhibitor NCT03591510 (CPKC412A2218) Indication Acute myeloid leukemia, pediatrics Phase Phase 2 Patients 22 Primary Outcome Measures Occurrence of dose limiting toxicities Safety and Tolerability Arms Intervention Chemotherapy followed by Midostaurin Target Patients Newly diagnosed pediatric patients with FLT3 mutated acute myeloid leukemia (AML) Readout Milestone(s) 2026 Publication TBD
Page 88
88 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic > Immunology > Neuroscience > Oncology > In-market Brands & Global Health Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Novartis Q3 Results | October 27, 2026 52 EDI048 NCT07249463 CRYPTONITE (CEDI048A12201) Indication Cryptosporidiosis infection Phase Phase 2 Patients 80 Primary Outcome Measures Average stool grade after the initiation of EDI048 or placebo treatment Arms Intervention 1) Experimental: EDI048. Participants will receive ABO809 as a single oral dose. If participant is symptomatic, then he/she would be randomized to get EDI048 administered orally. 2) Placebo Comparator: Placebo. Participants will receive ABO809 as a single oral dose. If participant is symptomatic, then he/she would be randomized to get placebo administered orally. Target Patients Healthy Adults Readout Milestone(s) 2027 Publication TBD
Page 89
89 Content Click below to navigate through the document Company overview Financial review References Conclusions Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations Appendix Novartis Q3 Results | October 27, 2026 Abbreviations Abbreviation Full form 1L First-line 2L Second-line 3L Third-line 6mCDP 6-month confirmed disability progression ADT Androgen Deprivation Therapy AEs Adverse events AH Antihistamines AHA American Heart Association AHJ American Heart Journal ARPI Androgen Receptor Pathway Inhibitor ARR Annualized Relapse Rate BRACEs Betaseron, Rebif, Avonex, Copaxone, Extavia CD20 Cluster of Differentiation 20 CDK4/6 Cyclin-Dependent Kinase 4 and 6 CHMP Committee for Medicinal Products for Human Use CIndU Chronic Inducible Urticaria CML Chronic Myeloid Leukemia CPUO Chronic Pruritus of Unknown Origin CSU Chronic Spontaneous Urticaria CVRR Cardiovascular Risk Reduction DM1 Myotonic Dystrophy Type 1 DMD44 Duchenne Muscular Dystrophy, Exon 44 DMT Disease-modifying therapy EAACI European Academy of Allergy & Clinical Immunology eBC Early Breast Cancer Abbreviation Full form EMA European Medicines Agency ESC European Society of Cardiology FA Food Allergy FDA Food and Drug Administration FPFV First Patient First Visit gMG Generalized Myasthenia Gravis H2H Head-to-Head HA Health Authority HCP Healthcare Provider HS Hidradenitis Suppurativa IgAN IgA Nephropathy ITP Immune Thrombocytopenia IV Intravenous LDL-C Low-Density Lipoprotein Cholesterol LN Lupus Nephritis mCRPC Metastatic Castration-Resistant Prostate Cancer mAPMN/S Metastatic Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer mBC Metastatic Breast Cancer MF Myelofibrosis mHSPC Metastatic Hormone-Sensitive Prostate Cancer MOTRx Units Normalized to Month-on-Therapy MRI Magnetic resonance imaging MS Multiple Sclerosis NBRx New-to-Brand Prescription NEDA-3 No evidence of disease activity-3 Abbreviation Full form NMPA National Medical Products Administration (China) NRDL China National Reimbursement Drug List nrSPMS Non-Relapsing Secondary Progressive MS OL Open-Label OLE Open-Label Extension OS Overall Survival PA Prior Authorization PBM Pharmacy Benefit Manager PIRA Progression independent of relapse activity PMR Polymyalgia Rheumatica PRV Priority Review Voucher Q2M Every 2 months dosing R3M Rolling 3 Months R4W Rolling 4 Weeks RMS Relapsing Multiple Sclerosis SD Symptomatic Dermographism SjD Sjögren's Disease SLE Systemic Lupus Erythematosus SpA Spondyloarthritis SPAF Stroke Prevention in Atrial Fibrillation SPMS Secondary progressive multiple sclerosis SSc Systemic Sclerosis TRx Total Prescriptions vHOT Video Hand Opening Time 37Novartis Q3 Results | October 27, 2026
Page 90
90 Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Novartis Q3 Results | October 27, 2026 References (1/2) 38Novartis Q3 Results | October 27, 2026 Pluvicto® (slide 8 references) 1 Data as of Sep 2026, monthly share, based on internal ordering system and analysis. Leqvio® (slide 10 references) 1 Includes PCSK9 monoclonal antibodies and bempedoic acid. 2 MOTRx Jul + Aug vs. PY. 3 Demand QTD as of Sep 30, 2026, vs. PY. 4 NBRx ending June 2026, IQVIA LAAD claims data. Kisqali® (slide 6 references) 1 IQVIA Market Sizing Monthly Report, Aug 2026, rolling 3 months; Data lag ~ 2 months. 2 eBC DE & UK NBRx monthly share from BEST as of Jun 2026 and Jul 2026 respectively. 3 IQVIA Aug 2026 Market Sizing Monthly Report. 4 BEST, NBRx (DE, UK, IT, ES, CA) monthly share as of Jun 2026; TRx top 5 countries (DE, UK, IT, ES, CA) as of Jun 2026. 5 Local ATU Tracking Study as of Jun 2026. 6 Slamon D et al. Adjuvant ribociclib + nonsteroidal aromatase inhibitor in patients with HR+/ HER2− early breast cancer: NATALEE 6 -year overall survival and efficacy outcomes. Presented at the European Society of Medical Onco logy (ESMO) Congress. October 23 -27, 2026. Madrid, Spain. Kesimpta® (slide 7 references) 1 TRx and NBRx adjusted data estimates through Sep 2026 based on data available through Sep 4, 2026. Data sources include Kesimpta: Contracted SP data + access card , Briumvi and Ocrevus IV: IQVIA LAAD adjusted by NSP, Ocrevus Zunovo: IQVIA Xponent and DDD and all other competitors: IQVIA NPA adjusted by NSP. 2 IQVIA MIDAS volume data Jun 2026, converted to patient equivalents using standard dosing assumptions. 3 Stethos TMM 2026.
Page 91
91 Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Novartis Q3 Results | October 27, 2026 References (2/2) 39Novartis Q3 Results | October 27, 2026 Scemblix® (slide 11 references) 1 US IQVIA CML market sizing repor t, Sep 2026 (up to Jun 2026 data month); N omenclature changed to more accurately reflect the IQVIA patient -level data used in this report. Underlying data set consistent with prior quarters. 2 Japan: MDV up to Q2 2026. 3 US NBRx share data US IQVIA CML market sizing report, Sep 2026 (up to Jun 2026 data month). 4 Ex-US: Rolling 3 months; EU4: IQVIA OD – Q2 2026, Germany: LRx – Q2 2026 and Japan: MDV – Q2 2026. 5 LRx monthly data as of Jun 2026. Cosentyx® (slide 12 references) 1 IQVIA NSOB National data WE 8/28 for MOTRx, WE 8/21 (Naive/Switch). Recent data is under review due to incorporation of Cosentyx bridge patients during the CMM -to-HealthDyne transition. 2 IQVIA mastered 867 WE 9/25, Q3 is partial through 12 weeks; IQVIA DDDMDI ME Jul 26. Rhapsido® (slide 13 references) 1 Internal Novartis analysis leveraging multiple data sources (SP Enhanced Xponent). 2 1L use, indicating patients using Rhapsido post-antihistamine failure, estimated using IQVIA claims (LAAD); Aug 2026 exit. 3 W/E 9/11 exit share, (Source: Rhapsido - SP Enhanced Xponent; Xolair & Dupi - Weekly IQVIA Xponent & DDD Data; Indication split using IQVIA LAAD claims weekly data) . 4 Internal Novartis international sales data. 5 https://www.novartis.com/us -en/news/media-releases/novar tis-rhapsido-remibrutinib-receives-fda-approval-first-treatment-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu. 6 Novartis target patient populations 2026: www.novartis.com/sites/novartis_com/files/novartis -target-patient-populations-2026.pdf. 7 Symptomatic Dermographism (SD), Cold (CU) and Cholinergic Urticaria ( CholU).